A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
a study on Thyroid Cancer
Medullary Thyroid Cancer medullary thyroid carcinoma targeted therapy Thyroid Neoplasms Carcinoma, Neuroendocrine Thyroid Diseases Selpercatinib Cabozantinib Vandetanib
Lead Scientist at UCSF
- Hyunseok Kang
Dr.Hyunseok "Hyu" Kang is a medical oncologist and a clinician scientist focusing on head and neck cancers including squamous cell carcinomas of head and neck (SCCHN), salivary gland cancers, thyroid cancers and other rare cancers of head and neck.
- accepting new patients
- Start Date
- Completion Date
- Loxo Oncology, Inc.
- Phase 3 Thyroid Cancer Research Study
- Study Type
- Expecting 400 study participants
- Last Updated